Bristol-Myers Squibb Company (BMY)vsEverpure, Inc. (P)
BMY
Bristol-Myers Squibb Company
$56.16
-0.16%
HEALTHCARE · Cap: $114.68B
P
Everpure, Inc.
$78.16
+2.77%
TECHNOLOGY · Cap: $25.26B
Smart Verdict
WallStSmart Research — data-driven comparison
Bristol-Myers Squibb Company generates 1224% more annual revenue ($48.48B vs $3.66B). BMY leads profitability with a 15.0% profit margin vs 5.1%. P appears more attractively valued with a PEG of 1.68. BMY earns a higher WallStSmart Score of 60/100 (C+).
BMY
Buy60
out of 100
Grade: C+
P
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.0%
Fair Value
$88.08
Current Price
$56.16
$31.92 discount
Intrinsic value data unavailable for P.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Strong operational efficiency at 33.0%
Large-cap with strong market position
Attractively priced relative to earnings
Earnings expanding 139.7% YoY
Revenue surging 20.4% year-over-year
Areas to Watch
2.6% revenue growth
Expensive relative to growth rate
Distress zone — elevated risk
Elevated debt levels
Expensive relative to growth rate
Trading at 17.8x book value
5.1% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BMY
The strongest argument for BMY centers on Return on Equity, Operating Margin, Market Cap.
Bull Case : P
The strongest argument for P centers on EPS Growth, Revenue Growth. Revenue growth of 20.4% demonstrates continued momentum.
Bear Case : BMY
The primary concerns for BMY are Revenue Growth, PEG Ratio, Altman Z-Score. Debt-to-equity of 2.55 is elevated, increasing financial risk.
Bear Case : P
The primary concerns for P are PEG Ratio, Price/Book, Profit Margin. A P/E of 138.3x leaves little room for execution misses.
Key Dynamics to Monitor
BMY profiles as a value stock while P is a growth play — different risk/reward profiles.
P carries more volatility with a beta of 1.44 — expect wider price swings.
P is growing revenue faster at 20.4% — sustainability is the question.
BMY generates stronger free cash flow (757M), providing more financial flexibility.
Bottom Line
BMY scores higher overall (60/100 vs 55/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Bristol-Myers Squibb Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Bristol Myers Squibb (BMS) is an American multinational pharmaceutical company, headquartered in New York City. Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Visit Website →Everpure, Inc.
TECHNOLOGY · COMPUTER HARDWARE · USA
Pandora Media, Inc. provides music discovery platform services in the United States and internationally. The company is headquartered in Oakland, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?